METASTATIC UVEAL MELANOMA

This study is testing whether a new combination of an oncolytic virus therapy (RP2) and an immunotherapy drug (nivolumab) works better than the current standard immunotherapy combination for adults with metastatic uveal melanoma, a rare and aggressive cancer that starts in the ey…

This study is testing a new oral drug called NBM-BMX for people with metastatic uveal melanoma, a rare type of eye cancer that has spread. The main goals are to find a safe and effective dose, learn about side effects, and see if the drug can shrink or slow the growth of tumors. …

This early-stage study is testing a personalized treatment called lifileucel for patients with advanced uveal melanoma (a rare eye cancer) or certain aggressive soft-tissue sarcomas. Doctors take a patient's own immune cells from their tumor, grow large numbers of them in a lab, …

This study is testing a two-step treatment for people with a rare and aggressive eye cancer (uveal melanoma) that has spread mainly to the liver. First, doctors use a procedure to deliver high-dose chemotherapy directly to the liver. The goal is to damage the tumors and potential…

This study is testing whether combining a newer immunotherapy drug (tebentafusp-tebn) with treatments that target the liver directly can better control metastatic uveal melanoma. It will enroll about 109 patients whose eye cancer has spread to the liver. The trial has two parts: …

This study is testing if a combination of two drugs, cemiplimab and Ziv-aflibercept, can help control metastatic uveal melanoma, a rare cancer that starts in the eye and spreads. The main goal is to see if the treatment can shrink tumors or stop them from growing. It will involve…

This study is testing a new drug called IDE196, both alone and combined with other drugs, for people with advanced cancers that have specific genetic changes (GNAQ/11 mutations or PRKC fusions). The main goals are to find safe doses and see if the treatments can shrink tumors. It…